Idexx Laboratories (IDXX) Q2 2025 10-Q Quarterly Report
Filed: Aug 4, 2025Period ending Jun 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Idexx Laboratories (IDXX) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 4, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Idexx Laboratories Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in provided excerpt
- • No segment or product line performance data presented
Idexx Laboratories Q2 2025 Quarterly FinancialsXBRL
Revenue
$1.1B
▲ +10.6% YoY▲ +11.1% QoQ
Net Income
$294M
▲ +44.6% YoY▲ +21.1% QoQ
Gross Margin
62.6%
▲ +92bp YoY▲ +18bp QoQ
Operating Margin
33.6%
▲ +734bp YoY▲ +192bp QoQ
Net Margin
26.5%
▲ +624bp YoY▲ +219bp QoQ
EPS (Diluted)
$3.63
▲ +49.4% YoY▲ +22.6% QoQ
Operating Cash Flow
$186M
▼ -25.2% YoY▼ -21.9% QoQ
Source: XBRL data from Idexx Laboratories Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Idexx Laboratories Quarterly Reports
Get deeper insights on Idexx Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.